The use of cryopreserved platelets in the treatment of polytraumatic patients and patients with massive bleeding
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F19%3A00541688" target="_blank" >RIV/60162694:G44__/19:00541688 - isvavai.cz</a>
Alternative codes found
RIV/61383082:_____/19:00000497 RIV/68407700:21460/19:00338739 RIV/00216208:11110/19:10399864
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/full/10.1111/trf.15177" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1111/trf.15177</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/trf.15177" target="_blank" >10.1111/trf.15177</a>
Alternative languages
Result language
angličtina
Original language name
The use of cryopreserved platelets in the treatment of polytraumatic patients and patients with massive bleeding
Original language description
BACKGROUND: The short shelf-life of fresh platelets limits their efficient inventory management and availability during a massive transfusion protocol. Risk of insufficient availability can be mitigated by building an inventory of cryopreserved platelets (CPs). METHODS: A comparative study of fresh apheresis platelets (FAPs) and CPs was performed. Type-O CPs were processed with DMSO frozen at -80°C and reconstituted in thawed AB plasma. All patients enrolled in the study had the following parameters evaluated on admission: vital signs (body temperature, heart rate, mean arterial pressure), blood count, prothrombin time, activated partial thromboplastin time, fibrinogen level, and, in trauma patients, international severity score. Several outcomes were evaluated: 30-day survival, adverse events, quantity of administered blood products, fibrinogen concentrate and thromboxane (TXA), and laboratory parameters after transfusion (blood count, prothrombin time, activated partial thromboplastin time, fibrinogen level). RESULTS: Twenty-five (25) patients in the study group received transfusions totaling 81 units of CPs. Twenty-one (21) patients in the control group received a total of 67 units of FAPs. There were no significant differences in patient characteristics (p > 0.05) between groups. Both groups were comparable in clinical outcomes (30-day survival, administered blood products, fibrinogen concentrate, TXA, and adverse events). Among posttransfusion laboratory parameters, platelet count was higher in the group transfused with FAPs (97.0 ×10 9 /L) than in the group transfused with CPs (41.5 ×10 9 /L), p = 0.02025. Other parameters were comparable in both groups. CONCLUSION: The study suggests that CPs are tolerable and a feasible alternative to FAPs. However, larger randomized studies are needed to draw definitive conclusions.
Czech name
—
Czech description
—
Classification
Type
J<sub>ost</sub> - Miscellaneous article in a specialist periodical
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Transfusion
ISSN
0041-1132
e-ISSN
1537-2995
Volume of the periodical
59
Issue of the periodical within the volume
S2
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
1474-1478
UT code for WoS article
000469482400010
EID of the result in the Scopus database
2-s2.0-85064269933